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PRM26
IMPact of UsIng EIthER MUltIPlIcatIvE oR addItIvE UtIlIty 
dEcREMEnts In dEcIsIon ModEls
Cure S.1, Despiégel N.2, Guerra I.1
1OptumInsight, Uxbridge, UK, 2OptumInsight, Nanterre, France
Objectives: In cost-utility analyses (CUAs) it is common to estimate the utility 
of patients while on treatment or when experiencing comorbidities by adjusting 
their baseline utility with the treatment/comorbidity-related utility decrement. 
This study assessed the impact of adjusting patients’ baseline utility with additive 
versus multiplicative utility decrements on the lifetime quality-adjusted life years 
(QALYs) in CUAs for two chronic illnesses. MethOds: Two Markov models were 
developed. In the first model, utility during treatment was obtained by adjust-
ing the baseline utility with the treatment-related utility decrement; treatment 
was given for one year. In the second model, utilities with comorbidities were 
obtained from external sources and were combined with the health state utilities 
by considering the lowest value. In both models, the response of the multiplicative, 
additive and the combined approach was investigated by comparing the number 
of QALYs gained over a lifetime. Results: In the first model, as treatment was 
only given during the first year, the impact on the number of QALYs gained over 
a lifetime was minimal. Thus, a similar incremental cost-effectiveness ratio per 
QALY (ICER/QALY) was obtained with all the approaches. In contrast, for the second 
model, the number of QALYs gained over a lifetime between the approaches was 
significantly different. This is because comorbidities were experienced during a 
longer period of time. Consequently, the difference in ICER/QALY was also substan-
tial. cOnclusiOns: When developing CUA, either a multiplicative or combined, 
rather than additive, approach should be used to calculate the utility of patients 
during treatment or with comorbidities, using utility decrements, if consider-
able uncertainty is present in the baseline utility. However, if QALYs gained with 
treatment or with comorbidities represent only a small fraction of the overall 
QALYs gained, the difference between the approaches is not expected to have a 
significant impact on the results.
PRM27
UnchaRtEREd tERRItoRy – analysIs of cRoss-BoRdER sERvIcE PRovIsIon 
WIthIn PUBlIc hEalth systEMs
Moran P., Teljeur C., Murphy L., O’Neill M., Harrington P., Ryan M.
Health Information and Quality Authority, Dublin, Ireland
Objectives: The European Union’s (EU) 2011 Directive on cross-border health care 
establishes the right of EU citizens to receive treatment abroad and be reimbursed 
in their home country. While the focus has been on patient mobility and access, it 
may also facilitate international outsourcing of services between countries. This 
research examines the methodological challenges in evaluating the costs and 
consequences of cross-border service provision. MethOds: Using the example 
of deep brain stimulation (DBS) treatment in Ireland, we conducted an economic 
analysis of the provision of cross-border services from the perspective of the public 
health system. This included an analysis of clinical and cost-effectiveness, ethical 
and societal implications and the challenges of integrating care between sepa-
rate health systems. Results: Accurate modelling of the provision of a new or 
expanded service serves as the basis for evaluating costs, impact on patients and 
potential gaps in continuity of care. Cost minimisation analysis may be appropriate 
under some circumstances, with due regard to the importance of patient selec-
tion and follow up. Cross-border services may have significant implications for 
equity of access, with potential negative consequences for those most in need of 
treatment. Results of the economic analysis indicate that a national DBS service 
in Ireland would cost an additional € 20,900 per patient over 10 years. The potential 
for anomalies within health systems with a mixture of private and public funders 
is highlighted, with the difference being reduced to € 4,100 per patient in a single 
payer scenario. cOnclusiOns: Health care funding structures can impact signifi-
cantly on the cost-effectiveness of cross-border services, even when differences in 
the actual cost of care are minimal. Given the externalities involved, analysis from 
the payer perspective may be too narrow for the economic evaluation of routine 
cross-border provision of elective services.
PRM28
EMPIRIcal EvIdEncE foR thE valIdIty and RElIaBIlIty of REsoURcE-UsE 
MEasUREs BasEd on PatIEnt REcall: a systEMatIc REvIEW
Thorn J., Noble S., Moore T., Hollingworth W.
University of Bristol, Bristol, UK
Objectives: Accurate measurement of resource use is required for economic 
evaluations alongside clinical trials. Patient-completed questionnaires are com-
monly employed as a means of collecting data; however, concerns over data qual-
ity persist, and there is little certainty about best practice. This review collates the 
evidence concerning the validity and reliability of resource-use measures based 
on patient recall with the aim of aiding health economists in developing better 
measures. MethOds: A search strategy incorporating terms covering health care 
resources, utilisation, patient-reported measures and validation/reliability con-
cepts was applied to the MEDLINE, EMBASE and PsycINFO bibliographic databases. 
Studies were included if they reported original research to inform costing studies, 
and were about patient or proxy self-reports of direct health care-related resource 
use in which a comparator (to assess validity or reliability) was specified. Studies 
were excluded if they were not in English or if they assessed general population 
surveys. Reference and citation lists of included studies were hand searched to 
identify additional studies. Data on study and population characteristics, type of 
instrument, recall period and sample size were extracted. Results and conclusions 
concerning the validity and reliability of reports of types of resource use consumed 
(e.g.medication, inpatient stays) were also extracted. Results: A total of 13,367 
abstracts were identified as potentially relevant through the database searches. 
Following abstract and full-text screening, 60 articles were deemed relevant, with a 
further 9 identified through hand searching. The majority focused on adults (60/69), 
with conventional DMARDs only. The sequence of treatments used after the fail-
ure of first biologic treatment was to be included as part of the cost-effectiveness 
modelling. We therefore built a model to match the treatment pathway for first-line 
biologics and beyond. MethOds: We researched the treatment pathway and exist-
ing cost-effectiveness models in order to create an appropriate model. We rebuilt 
the model used by the technology assessment group in TA195, which considered 
second-line biologics and beyond. We adapted this model to reflect the current 
treatment pathway and consider first line biologics. Results: We created a patient 
simulation model, which generated a cohort of virtual patients and tracked their 
costs and QALYs over the pathway. Patients began treatment with a biologic, and 
could discontinue at month 6 due to an adverse event (AE), in which case they 
switched to a different biologic, with first-line efficacy. Patients who did not have 
an AE discontinued at month 6 if their DAS 28 improvement was insufficient. After 
discontinuation at month 6, or later, patients next received rituximab, unless con-
traindicated. If rituximab was contraindicated, or the patient had an AE by month 
6, they moved onto another biologic treatment, after which they received a DMARD 
treatment sequence (including palliative care). Patients who had insufficient DAS28 
response on rituximab at month 6 switched to tocilizumab (unless received previ-
ously), after which they received the DMARD sequence. Patients who had sufficient 
DAS28 improvement with rituximab remained on rituximab long-term, until they 
received the DMARD treatment sequence. Patients could exit the model at any point 
if they died. cOnclusiOns: We used robust methodology and clinical rationale to 
assess the cost-effectiveness of licenced treatments reflected across NICE’s recom-
mended treatment pathway for RA.
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ModEllIng thE cost-EffEctIvEnEss of fIRst lInE BIologIcs foR 
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Objectives: In 2013, NCPE assessed the cost-effectiveness of subcutaneous (SC) 
abatacept as a first line biologic for the treatment of rheumatoid arthritis (RA), 
compared to existing biologics. It was necessary to consider the treatment path-
way beyond first line biologics. We therefore built a model to match the treatment 
pathway for first line biologics and beyond. MethOds: We used our individual 
patient sampling model for England and Wales as a starting point to create a model 
which considers biologic cycling, to match the treatment pathway in Ireland. We 
differentiated between the efficacy of a biologic at first line, and at second line 
or later. Results: We created a model which could be used to calculate the cost-
effectiveness of biologics for the treatment of RA in Ireland. Patients first received 
treatment with SC abatacept, intravenous abatacept, adalimumab, etanercept, 
infliximab, certolizumab pegol or golimumab. If they experienced an adverse event 
(AE) on that treatment within 6 months, they switched to another biologic at first 
line efficacy. If not, their response to treatment was tested using the DAS28: if this 
improved by 1.2 or more, their time on treatment was sampled from a Weibull 
distribution, otherwise they discontinued at month 6. The patient then moved onto 
a randomly sampled second line biologic, which was either one of the first line bio-
logics or rituximab. The time on second line biologic was sampled from a Weibull 
distribution, and then the patient moved onto a third line biologics (second line 
biologics and tocilizumab). The patient cycled through the biologics until they died, 
or had received all 8 treatments. After 8 biologics, remaining patients received 
leflunomide, cyclosporin, azathioprine and palliative care. cOnclusiOns: We 
used robust methodology and clinical rationale to model the treatment pathway of 
biologics for RA in Ireland and facilitated cost-effectiveness comparison between 
first line biologics.
PRM25
a systEMatIc REvIEW of EconoMIc EvIdEncE In hEPatItIs c: MEthods 
UsEd In REcEnt EconoMIc EvalUatIons
Woods M.S.1, Kiri S.2, Ling C.1, McCrink L.1, Zimovetz E.1, Hass B.3
1RTI Health Solutions, Manchester, UK, 2Boehringer Ingelheim Ltd., Bracknell, UK, 3Boehringer 
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Objectives: To perform a systematic literature review of economic evidence 
for genotype 1 hepatitis C virus (HCV) treatments and to summarise and assess 
the methods used in recent economic evaluations. MethOds: Multiple data-
bases were searched to identify economic evaluations in patients with genotype 
1 HCV. Detailed review methods are presented elsewhere. Results: 53 economic 
analyses and 17 Health Technology Assessment (HTA) documents were identified. 
Most economic analyses were performed using lifetime horizon Markov models, all 
for interferon-containing regimens. Most were performed in the United Kingdom 
(UK) (n = 13), United States (n = 13), or Germany (n = 7). Two recent National 
Institute for Health and Care Excellence (NICE) submissions were included: tel-
aprevir triple therapy (with peginterferon plus ribavirin) and boceprevir triple 
therapy, for previously treated and untreated patients. The models used were 
different; however their structures and some inputs were based on previous 
NICE appraisals for peginterferon plus ribavirin. There were a number of limita-
tions found in the included economic evaluations, which may have affected the 
cost-effectiveness outcomes: 1) The models did not adequately capture all health 
benefits and costs in their quality-adjusted life-year calculations; 2) The models 
did not account for the possibility of benefits caused by reduced transmission of 
HCV; 3) The models did not incorporate patient factors that may influence disease 
progression; 4) Modelling of subgroups may have been insufficient, particularly 
as the understanding of patient and viral factors that predict treatment response 
grows; and 5) Some made generalisations for the compensated cirrhosis popula-
tion that were not comparable with the UK population. cOnclusiOns: Recent 
economic models have generally adhered to previous iterations of HCV models and 
have not evolved with our knowledge of the disease. In light of upcoming treat-
ment alternatives, model refinement may be necessary to capture the increasingly 
complex treatment decisions that will be required.
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studies, including and in addition to the EQ-5D, are extracted and added to the data-
base record to create a searchable index of instruments. A beta version of the data-
base, using bespoke software to improve functionality, is currently undergoing ad hoc 
testing. Results: The alpha version of the database contains over 3,500 potentially 
relevant studies identified by the search process. Several hundred studies have been 
data extracted and indexed. The names of over 50 instruments, including quality of 
life, disease specific and generic preference-based measures have been added to the 
index. A programme of sifting, data extraction and indexing is ongoing. Public access 
to the beta version of the database is planned for Autumn 2013. cOnclusiOns: 
The purpose of the health utilities database is to improve access to HSUV evidence, 
in the first instance in studies using the EQ-5D with a view to including all major 
preference-based utility measures.
PRM33
thE REvIEW of PUBlIcatIons of PhaRMacoEconoMIc REsEaRch In 
RUssIa dURIng 2007-2012
Yagudina R.1, Kulikov A.1, Mirkasimova G.1, Litvinenko M.2
1I.M. Sechenov First Moscow State Medical University, Moscow, Russia, 2First Moscow State 
Medical University named after I. M. Sechenov, Moscow, Russia
Objectives: To analyze the publications on methodology and normative regu-
lations of pharmacoeconomic studies, including materials providing results of 
conducted researches in Russia or translated international publications, as well 
as to analysis the dynamics of publications and identify the structure of meth-
odological approaches in Russia. MethOds: The screening of publications from 
the data of the Central Medical Scientific Library of the First MSMU was conducted 
based on the key words - “pharmacoeconomic*” and “pharmacoeconomical*” with 
corresponding endings. The time horizon of the study was 6 years (from 2007-
2012). Results: By the beginning of 2013, 280 literature sources were found and 
analyzed in the timeline from 2007 to 2013. It was found that the most common 
type of publications for the reporting period have been the inaugural dissertations 
showing the researches results - they are accounted for about 47% of all studies, 
followed by further research reports, accounted for 44%, methodical publications 
- 5%, dissertations devoted to the methodology of the pharmacoeconomics- 3%, 
regulatory guidance documents and translations of foreign studies - 1%. The most 
common structure of published researches was monocenter (56%), with a retro-
spective time-restricted directivity (74%). Russian authors use the methodology of 
the “cost-effectiveness” analyzing in their works the most frequently (48%). 64% of 
Russian researchers take into account only direct costs, 32% of researchers analyze 
their studies based on indirect costs. cOnclusiOns: Based on our review of the 
published works from 2007 to 2012, we can make a conclusion on the formation 
and development of high-grade pharmacoeconomics as an independent research 
area in the Russian Federation.
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EvalUatIng dIffEREnt ModEs of RadIothERaPy BasEd on a PatIEnt-
lEvEl sIMUlatIon ModEl
Quik E.H.1, Feenstra T.L.1, Postmus D.1, Krabbe P.F.M.1, Langendijk H.2
1University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, 
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Objectives: Use of proton instead of photon radiation therapy for head and neck 
cancer reduces the primary tumor and damage to adjacent organs risk, which 
results in fewer complications. These complications decrease quality of life (QOL). To 
support better decision making concerning which patients benefit most from pro-
ton therapy, a patient-level simulation model is developed and applied to compare 
outcomes. MethOds: Model estimates, such as patient and tumor characteristics, 
follow-up time, and survival, were based on patient-level data containing patients 
treated with radiation therapy as first line therapy for head and neck tumor in The 
Netherlands between 1980–2010 at the UMC Groningen (n= 277) and VU Amsterdam 
(n= 736). In silico radiation treatment planning schemes for both proton and photon 
therapy allowed to compare a priori expected health benefits and cost consequences 
for both therapy modes to support a patient tailored choice. Results: Patients 
experienced their first event at a median time of 30 (0-270, SD 34) months’ time. 
Loco-regional recurrency in 29%, distant metastasis in 4.2%, both combined in 1% 
and dead in 13.3% of patients. Cost per year for photon was estimated € 15000, proton 
€ 30000, disease free state € 190, local regional recurrence € 28000, metastases € 35000, 
and both € 35000. For the complication sticky saliva costs per year of an average 
patient were € 31, xerostomia € 194, dysphagia € 57, tube feeding € 4262, and hypothy-
roidism € 117. Proton radiation therapy leads to less complications and improved 
QOL. cOnclusiOns: Given the high costs of proton therapy, this was found not 
to be cost-effective compared to best photon therapy in an average patient with 
head and neck cancer. However, the outcomes vary substantially between patients. 
Depending on patient and tumor characteristics for selected patients with high 
complication risks, proton therapy can be a better option.
PRM35
thE EconoMIc footPRInt of thE gREEk PhaRMacEUtIcal IndUstRy
Tserkezis E., Paratsiokas N., Tsakanikas A., Athanasiadis A.
Foundation for Economic & Industrial Research (IOBE), Athens, Greece
Objectives: To assess the overall impact of the production and distribution of 
pharmaceutical products in the Greek economy, in terms of Value Added, GDP, 
employment and tax revenues. MethOds: The overall impact in the Greek econ-
omy is estimated as an exogenous change in the economic activity by using the 
Leontief input-output model. Results: The results indicate that the direct effect 
of the industry on domestic economic activity is € 1.5 billion in terms of GDP. The 
indirect effect, which represents the value created by auxiliary sectors as (main 
suppliers) of the pharma industry is € 2.2 billion. Finally, the induced effect, which 
is the impact from the final consumption, as a result of the wages and salaries 
gained by employees across the production chain of the specific industry is € 3.8 
billion. Hence, the overall effect on GDP is approximately € 7.5 billion, which repre-
and nearly half originated from north America (31/69). Emerging themes suggest 
that better accuracy is achieved when patients are answering questions about inpa-
tient and specialist care. cOnclusiOns: There is only a limited amount of valid-
ity and reliability information available to inform best practice for resource-use 
measurement in clinical trials. This ongoing review will identify the gaps, giving a 
clearer view of where research efforts should be concentrated.
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fUtURE costs InclUsIon In PUBlIshEd EconoMIc EvalUatIons: What Is 
thE cURREnt sItUatIon?
Gros B.1, Soto J.2, Casado M.A.1
1Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, 2Carlos III University of Madrid, 
Madrid, Spain
Objectives: Nowadays, there is a general agreement about the need of includ-
ing future related medical costs in life years gained while no consensus has been 
achieved about future unrelated medical costs (indirect medical costs) and future 
non-medical costs. The aim of this study has been to assess the extension of 
published economic evaluations that incorporated future costs and what types 
of future cost were included. MethOds: Three general health economic journals 
(Pharmacoeconomics, Value in Health and European Journal of Health Economics) were 
reviewed to identify economic evaluations from 2008 to 2011. Only complete eco-
nomic evaluations were accepted for this research. From each selected article, future 
cost inclusion was evaluated along with the type of future costs included. Results: 
A total of 148 articles were founded from the three journals fulfilling the inclusion 
criteria; 67 of them (45.27 %) incorporated future related medical costs, 9 (6.08 %) 
included also future unrelated medical costs and none included future non-medical 
costs. Percentage of articles including future costs increased from 2008 (33 %) to 
2011(57 %) and no differences were detected between the three journals in the pro-
portion of economic evaluations incorporating future costs. cOnclusiOns: Despite 
most of health economic guidelines advice the need of incorporating future costs in 
l economic evaluations, less than the half of articles reviewed incorporated them. 
Moreover, the inclusion of future unrelated medical costs and future non-medical 
costs was much lower. Results of economic evaluations can change dramatically 
depending on future costs inclusion. It is necessary to change the current practice 
and systematically include future related medical costs in the base case of economic 
evaluations and future unrelated medical costs and future non medical costs at 
least in sensitivity analysis.
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Objectives: A range of linked electronic health records (LEHR) datasets are 
becoming available in the NHS in England. Understanding the benefits such large 
LEHR datasets can offer when performing cost-effectiveness analysis and over-
coming the challenges inherent in utilising such datasets using as a case study: 
the CALIBER (Cardiovascular Disease Research using Linked Bespoke Studies and 
Electronic Records) dataset to assess the cost-effectiveness of treatment of patients 
with chronic stable angina. MethOds: The CALIBER dataset links primary care 
data from CPRD with secondary care data from HES, mortality data from ONS and 
disease-specific data from MINAP. This dataset is used to provide a generalisable 
baseline for cost-effectiveness models and to provide effectiveness estimates for 
treatments observed in the dataset. It is also used to explore decisions that, due 
to ethical concerns, could not be researched through RCTs - for example, optimal 
durations and combinations of treatments used in current practice. The statistical 
methods of matching, differences in differences and instrumental variables are 
used to overcome the selection bias problems associated with inferring treatment 
effects using observational data. The models are also combined with RCT results 
for novel treatments to assess their cost-effectiveness in a real world as opposed to 
trial setting. Results: There were significant challenges involved in working with 
LEHR ranging from correctly linking the data to plausibly imputing missing data 
and correcting for selection bias in estimates. Having addressed these challenges 
we were left with a rich dataset, from which to estimate costs, risks of health events 
and treatment effects in a generalisable real world setting. cOnclusiOns: While 
the selection biases associated with the use of LEHR within the NHS makes them 
challenging to work with, the large sample sizes, generalisability of the results 
and relatively low cost of the research makes them a hugely valuable resource for 
economic evaluation.
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dEvEloPMEnt of thE schaRR hUd (hEalth UtIlItIEs dataBasE)
Rees A., Paisley S., Brazier J., Cantrell A., Poku E., Williams K.
University of Sheffield, Sheffield, UK
Objectives: The retrieval of studies containing evidence of health state utility val-
ues (HSUVs) is currently problematic using generic bibliographic databases such as 
Medline. This is due to a lack of standardised search vocabulary and inadequate and 
inconsistent indexing. The objective of this project is to develop a bibliographic data-
base providing access to details of research studies containing health state utility val-
ues generated using the EQ-5D and other preference-based instruments. MethOds: 
The initial phase of the project has focussed on the EQ-5D. An alpha version of the 
database was created using Mendeley reference management software. A corpus of 
potentially relevant studies was identified by searching Medline and by sifting the 
reference lists of systematic reviews of HSUVs in a range of diseases and conditions. 
The sifting of retrieved studies is an ongoing process. Studies are included in the 
database if they contain estimates of HSUVs. The names of instruments used in the 
